查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球水產養殖疫苗市場-2022-2029
市場調查報告書
商品編碼
1129258

全球水產養殖疫苗市場-2022-2029

Global Aquaculture Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

水產養殖疫苗的創新有望推動市場增長。

隨著技術的進步，Elanco 研發出一種新的鮭魚病毒疫苗，即核酸疫苗。這些疫苗接種提供了一種更有效的方法來保護鮭魚免受病毒感染。核酸疫苗僅具有導致抗原形成的病原體的相關遺傳成分。這些元素被放入稱為質粒的環狀核酸結構中，當注射到肌肉中時，它會指示細胞以模擬對真實感染的免疫反應的方式製造抗原。核酸疫苗只含有一小部分病毒，因此沒有傳播疾病的風險。

此外，根據全球海鮮聯盟的說法，植物性魚類疫苗有可能為養殖魚類提供低成本、高安全性和有效的保護。疫苗植物工廠的可行性、有效性和安全性已在多項臨床前和臨床研究中得到證明。基於植物的平台為重組亞單位疫苗提供了引人注目的優勢。植物性疫苗不存在活疫苗的安全問題。與基於哺乳動物的生產系統相比，在基於植物的系統中沒有發現不需要或有害的成分，例如細菌毒素或酵母衍生的不需要的蛋白質。此外，植物衍生系統與天然衍生系統一樣，具有很高的生物合成能力，可以增強疫苗的免疫原性。由植物製成的口服疫苗是最好的。製造過程簡單，無需額外的醫療設備進行注射。高純度植物性疫苗提高了疫苗接種的便利性，增強了免疫反應。當口服疫苗抗原時，它們會通過胃並被腸道吸收，從而引發免疫反應。可以通過低成本、安全和高效的植物性疫苗接種來保護養殖魚類。由於這些原因，預計市場在預測期內將擴大。

約束

水產養殖疫苗生產和批准的嚴格監管政策以及復雜的疫苗開發方法可能是預測期內阻礙市場增長的因素之一。

行業分析

水產養殖疫苗市場根據供應鏈分析、價格分析等各種行業因素對市場進行深入分析。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了積極影響。水產養殖者正在實施保守的養殖策略，以減少接觸 COVID-19 危害並防止價格下跌造成的經濟損失，預計 2020 年總產量將下降 1.3%。這些數字未經證實，但這將標誌著近 60 年來全球水產養殖產量首次出現年度下降，與前幾年 4-5% 的穩定增長率大相徑庭。然而，由於生長速度、生產週期長度、市場需求等方面的差異，影響的強度和生產者的反應因物種而異。同樣重要的是要了解，對於一些養殖物種，在最初的生產中斷後市場供應可能需要一段時間才能改變。此外，由於勞動力減少以及 COVID-19 傳染病疫苗生產趨勢的變化，水產養殖疫苗生產的減少也對市場產生了影響。因此，從上述描述來看，隨著經濟活動的恢復，預計市場將受到影響並迅速獲得牽引力。

全球水產養殖疫苗市場報告提供大約 45 多個市場數據表、40 多個數字和 200 頁結構。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 水產養殖疫苗的創新有望推動市場增長。
    • 限制因素
      • 預計水產養殖疫苗生產和審批方面的嚴格監管政策將阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 減毒活疫苗
  • 滅活□□疫苗
  • 亞單位疫苗
  • DNA 疫苗
  • 重組疫苗

第 8 章給藥途徑

  • 口語
  • 注入
  • 沉浸式
  • 其他

第 9 章按應用程序

  • 細菌感染
  • 病毒感染
  • 寄生蟲感染
  • 其他

第 10 章按魚類分類

  • 羅非魚
  • 鱒魚
  • 三文魚
  • 鱸魚
  • 皮脂
  • 其他

第 11 章，最終用戶

  • 獸醫醫院
  • 獸醫醫院
  • 其他

第 12 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 13 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 14 章公司簡介

  • 默克公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Tecnovax
  • Hipra
  • Zoetis LLC
  • Phibro Animal Health Corporation
  • Elanco
  • KBNP, INC.
  • Kyoto Biken Laboratories, Inc.
  • Veterquimica S.A.
  • Virbac S.A.

第 15 章全球水產養殖疫苗市場-DataM

簡介目錄
Product Code: DMVH5834

Market Overview

Aquaculture Vaccines Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

A protective immune response is created in an animal during vaccination through administering vaccinations. Antigens from pathogenic organisms that have been turned non-pathogenic through various processes are used in vaccines to stimulate the animal's immune system and raise its resistance to disease when pathogens are met naturally. Vaccination is an easy, effective and preventive method of protecting fish from diseases.

Market Dynamics

Innovation in aquaculture vaccines is expected to drive market growth.

Due to its technological advancements, Elanco has created a new class of salmon virus vaccinations known as nucleic acid vaccines. These immunizations provide a more focused method for protecting salmon from viral infections. Only the relevant genetic elements of the pathogen that cause the formation of an antigen are present in nucleic acid vaccines. These elements are placed into a plasmid, a circular nucleic acid structure, which, when injected into a muscle, instructs cells to manufacture antigens in a manner that resembles the immunological response to a genuine infection. Nucleic acid vaccines do not risk spreading the illness because they only contain a small portion of the virus.

Moreover, according to the global seafood alliance, Plant-based fish vaccines could provide low-cost, high safety and effective protection for farmed fish species. The viability, effectiveness, and safety of plant factories for vaccines have been demonstrated in several pre-clinical and clinical trials. A plant-based platform offers attractive benefits for recombinant subunit vaccines. The safety issues with live vaccinations are not present with plant-based vaccines. In contrast to mammalian-based production systems, undesirable or harmful components, such as bacterial toxins and undesired proteins from yeast, have not been discovered in plant-derived systems. Like naturally occurring systems, plant-based systems have a high capacity for biosynthesis, which boosts the immunogenicity of vaccines. Oral vaccinations made from plants are the best. The production procedure is straightforward, and injection does not require the use of any additional medical equipment. High purity plant-based vaccines make vaccination more convenient and boost immune responses. When vaccine antigens are consumed orally, they pass past the stomach and are absorbed in the intestine, triggering immunological reactions. Fish raised on farms could be protected with low-cost, highly safe, and efficient plant-based vaccinations. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint

Stringent regulatory policies for the manufacturing and approving of aquaculture vaccines and complicated vaccine development approaches are some factors the market is expected to hamper the market growth in the forecast period.

Industry Analysis

The aquaculture vaccines market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted healthcare systems and the market. Aquaculture farmers have implemented conservative stocking strategies to lessen their exposure to COVID-19 hazards and prevent financial losses in the face of declining pricing, which is expected to result in a 1.3 percent decrease in total output in 2020. Although this number hasn't been verified, it would represent the first yearly fall in worldwide aquaculture production in nearly 60 years and a striking break from the steady 4-5 percent pace of growth seen over the past few years. However, due to the variations in growth rates, lengths of production cycles, and market demands, the impact's intensity and the producers' response have varied greatly depending on the species. It's also crucial to understand that market supply for some aquacultured species may take some time to change after early production process disturbances. Additionally, the decrease in aquaculture vaccine manufacturing caused by the reduced workforce combined with changing trends to produce a vaccine for COVID-19 infection has also impacted the market. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Inactivated Vaccines segment is expected to hold the largest market share in aquaculture vaccines market

The inactivated vaccines segment is expected to dominate in 2021. The segment benefits because the process of killing a pathogen that is cultivated and then turned into a vaccine is used to create inactivated vaccinations, also referred to as killed vaccines. These vaccines are the ones that are typically used to prevent various bacterial and viral infections. Moreover, Strong immune responses are produced by inactivated vaccines by keeping the inactive genetic component, and the virus surface exposed antigens are crucial for a strong immune response. Additionally, since inactivated vaccination does not persist in the environment or in the fish that have received it, it is safe, which increases demand. Although regular dosages are necessary, there is very little possibility of a pathogen returning or interfering with the system. One of the most widely used vaccines that are also legally and commercially available is inactivated vaccines. Certain vaccines are available for disorders, including infectious salmon anemia and infectious pancreatic virus, among others. Therefore, it has increased the demand for inactivated aquaculture vaccines. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global aquaculture vaccines market

In 2021, North America accounted for the highest revenue share. The market's increasing research and development investment, government support for aquaculture vaccine development, product launches and acquisitions by the key regional players are some of the factors the market is expected to boost in the forecast period. For instance, the University of Florida received planting solutions grant from the Foundation for Food & Agriculture Research (FFAR) in February 2021 for around USD 790,326. The goal of this investment was to aid in the creation of a vaccine delivery method that will stop the tilapia lake virus and other diseases from spreading inside the aquaculture sector. Moreover, in July 2020, Zoetis acquired Fish Vet Group from Benchmark Holdings, PLC. This added to the company's Pharmaq business, which is involved in fish vaccines and services. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the aquaculture vaccines market are Merck & Co., Inc., Tecnovax, Hipra, Zoetis LLC, Phibro Animal Health Corporation, Elanco, KBNP, INC., Kyoto Biken Laboratories, Inc., Veterquimica S.A., Virbac S.A.

Merck & Co., Inc.:

Overview:

Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biological therapies and animal health products. The company's operations are principally managed on a product basis and include two operating segments, the pharmaceutical and animal health segments, both reportable. The company offers vaccinations, poultry, cattle, and aquaculture products, among other animal health items. Merck provides managed healthcare services to hospitals, government organizations, wholesalers, retailers, and hospitals. It also provides veterinarians, distributors, and animal producers with animal health products. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Outside of North America and Canada, Merck is known as MSD, and its global headquarters are in Kenilworth, New Jersey.

roduct Portfolio:

AQUAVAC IridoV: AQUAVAC IridoV, an oil-adjuvanted vaccine, is administered intraperitoneally as a single-injection dose to fish weighing no less than 5 grams. Fish susceptible to this disease include species such as Asian seabass, grouper, pompano and Japanese yellowtail.

The global aquaculture vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 200pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovation in aquaculture vaccines is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent regulatory policies for the manufacturing and approving of aquaculture vaccines are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Attenuated Live Vaccines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Inactivated Vaccines
  • 7.4. Subunit Vaccines
  • 7.5. DNA Vaccines
  • 7.6. Recombinant Vaccines

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Injected
  • 8.4. Immersion
  • 8.5. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Bacterial Infection*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Viral Infection
  • 9.4. Parasitic Infection
  • 9.5. Others

10. By Species Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 10.1.2. Market Attractiveness Index, By Species Type Segment
  • 10.2. Tilapia*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Trout
  • 10.4. Salmon
  • 10.5. Seabass
  • 10.6. Seabream
  • 10.7. Others

11. By End user

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.1.2. Market Attractiveness Index, By End user Segment
  • 11.2. Veterinary Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Veterinary Clinics
  • 11.4. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. Merck & Co., Inc.*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Tecnovax
  • 14.3. Hipra
  • 14.4. Zoetis LLC
  • 14.5. Phibro Animal Health Corporation
  • 14.6. Elanco
  • 14.7. KBNP, INC.
  • 14.8. Kyoto Biken Laboratories, Inc.
  • 14.9. Veterquimica S.A.
  • 14.10. Virbac S.A.

LIST NOT EXHAUSTIVE

15. Global Aquaculture Vaccines Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us